Spain’s mid-sized pharma company Almirall SA is to use cash from the sale of its respiratory franchise to AstraZeneca PLC to become a “top global player in dermatology”, a move already underway with the purchase of U.S. dermatology-focused Aqua Pharmaceuticals LLC in December 2013.
The AZ deal, valued at around $2 billion and completed at the beginning of November [See Deal], allows Almirall to move aggressively “but prudently” towards a specialty pharma model, CEO Eduardo Sanchiz
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?